Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunogenicity and Safety of BBV87 Chikungunya Vaccine in Healthy Subjects
NCT07555392Phase 3Recruiting
- Sponsor
- Bharat Biotech
- Start
- Apr 2026
- Primary completion
- Sep 2026
- Modality
- Whole Inactivated Vaccines
- Countries
- 1
01
Overview
A Phase 3 trial of BBV87 in chikungunya virus infection, sponsored by Bharat Biotech. Started Apr 2026; status: recruiting.
02
Drugs
BBV87
03
Conditions
chikungunya virus infection
Beyond the preview
Go deeper on NCT07555392.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07555392.